For Healthcare Professionals

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

clipboard-pencil

About the study

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
  2. Adequate Bone Marrow Function.
  3. Adequate Renal & Liver Function.
  4. Adequate Performance Status

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
  2. Previous high-dose chemotherapy requiring allogenic stem cell rescue.
  3. Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Metastatic Cancer,Solid Tumor,Advanced Cancer,NonHodgkin Lymphoma

Age (in years)

18+

Phase

Phase 1

Participants needed

174

Est. Completion Date

Feb 1, 2024

Treatment type

Interventional


Sponsor

ALX Oncology Inc.

ClinicalTrials.gov identifier

NCT03013218

Study number

AT148001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.